ArticleCureus2026
Monocyte-to-Platelet Ratio Shows Modestly Improved Discrimination Over Model for End-Stage Liver Disease (MELD) 3.0 in Predicting 1-Year Mortality in Patients With Chronic Liver Failure and Hepatic Encephalopathy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background This study aimed to develop a noninvasive prognostic model to predict 1-year mortality in patients with chronic liver failure (CLF) and hepatic encephalopathy (HE). Methods Clinical data from 285 patients with CLF and HE admitted between January 2010 and April 2024 were analyzed. Multivariate logistic regression analysis was performed to identify independent risk factors associated with 1-year mortality. Results Among the 285 patients, 99 (34.7%) died within one year of follow-up. Compared with survivors, non-survivors were older (Z = 3.585, P < 0.01) and had significantly higher Model for End-Stage Liver Disease (MELD), MELD sodium (MELD-Na), and MELD 3.0 scores (Z = 2.863, 2.768, and 2.849, respectively; all P < 0.01). Multivariate regression analysis identified age, monocyte-to-platelet ratio (MPR), lymphocyte count, and alanine aminotransferase (ALT) levels as independent predictors of 1-year mortality (all P < 0.01). A novel prognostic model, Model_age_MPR_Lym_ALT, was developed, demonstrating superior discriminatory power compared to Child-Pugh, MELD, MELD-Na, and MELD 3.0 scores (all P < 0.01). Based on an optimal cutoff value of 0.352, patients were stratified into low-risk (<0.352) and high-risk (≥0.352) groups, with 1-year mortality rates of 21.38% (34/159) and 51.59% (65/126), respectively. Additionally, stratification by age (≥65 years vs. <65 years) demonstrated that the novel model outperformed the traditional scores in the older subgroup. Conclusion The proposed noninvasive model, incorporating age, MPR, ALT, and lymphocyte count, may serve as a practical and reliable tool for predicting 1-year mortality in patients with chronic liver failure and hepatic encephalopathy. However, given the retrospective, single-center design, these findings lack external validation and require confirmation in prospective multicenter studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.